ARCHIVED - Recommendations on a Human Papillomavirus Immunization Program

Table of Contents

• Executive Summary

• 1. Background
• 2. Burden of Disease
• 3. HPV Vaccine Characteristics
• 4. Immunization Strategies
• 5. Cost-Effectiveness of HPV Immunization
  • 5.1 International Modelling Studies
  • 5.2 Canadian Modelling Studies
• 6. Acceptability of HPV Immunization
  • 6.1 International Studies
  • 6.2 Canadian Studies
7. Feasibility of Eventual HPV Immunization
• 8. Ability to Evaluate Immunization Programs
  • 8.1 Availibility of Systems to Measure Coverage and Vaccine Utilization, and Quality of Vaccination Services
  • 8.2 Availibility of Systems to Measure Impact of HPV-Related Infections
  • 8.3 Availibility of Systems for Linking Health Outcomes Databases, Immunization Registeries, and Population Registries
• 9. Research Questions
  • 9.1 Fundamental Research
  • 9.2 Intervention Research
  • 9.3 Program Delivery Research
• 10. Equity, Ethical, and Other Considerations
  • 10.1 Equity
  • 10.2 Ethical Considerations
  • 10.3 Other Considerations
• 11. CIC Recommendations
  • 11.1 Goals
  • 11.2 CIC-NACI Working Group Recommendations on Disease Incidence Reduction
  • 11.3 CIC-NACI Working Group Recommendations on HPV Immunization Strategies and Programs
    • 11.3.1 Routine Immunization
    • 11.3.2 Catch-up Immunization
    • 11.3.3 Immunization Schedules
    • 11.3.4 Impact of Vaccination on cervical Cancer Screening
• 11.4 CIC/NACI Working Group Recommendations on Program Evaluation
• Appendices
  • Appendix 1
  • Appendix 2
  • Appendix 3
  • Appendix 4
  • Appendix 5
  • Appendix 6
• References